← Sagimet Biosciences Inc. (SGMT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Sagimet Biosciences Inc. (SGMT)
Pharmaceutical Preparations · market cap $643M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Sagimet Biosciences (SGMT) is a small-cap pharma with 14 employees and a ~$226M market cap, built around a single clinical-stage asset, TVB-2640, being evaluated in Phase 2 for MASLD/MASH. With $36.6M in cash (~12.8 months runway), no revenue, and ~$39M in annual R&D spend, the company faces a near-term financing imperative alongside its clinical execution challenge.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TVB-2640 25 mg (US) | Phase 2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) |
| TVB-2640 | Phase 2 | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease |
Price & technical context
3-month
+18.2%
6-month
+72.0%
12-month
+31.1%
52-wk range
$4.55–$11.17
vs 50-day MA
-6.1%
vs 200-day MA
+27.6%
Realized vol
82.2%
Max drawdown
-72.0%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SGMT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.